News Daily News CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally Michael O'Riordan December 14, 2022
News Daily News Shifting Acute MI Outcomes by Medicare Type: A Window Into Insurer’s Influence L.A. McKeown December 09, 2022
News Daily News A Simple Nudge Moves the Needle on Statin Prescribing Michael O'Riordan December 02, 2022
News Daily News Many STEMI Patients Not Treated Within National Time Goals Michael O'Riordan November 15, 2022
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD Shelley Wood November 06, 2022
News Conference News AHA 2022 BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI Shelley Wood November 06, 2022
News Daily News New Biomarker-Based Risk Score Performs Well in ACS Michael O'Riordan October 25, 2022
News Daily News COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review Todd Neale October 12, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Conference News ESC 2022 Polypill Bests Usual Care in Patients With Recent MI: SECURE Michael O'Riordan August 26, 2022
News Daily News After COVID-19, Unvaccinated at Risk for Long-term CVD Complications Michael O'Riordan August 16, 2022
News Daily News Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution Michael O'Riordan August 11, 2022
News Daily News LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD Michael O'Riordan July 11, 2022
News Daily News Following Takotsubo, Men Have Worse Outcomes, Are More Likely to Die Than Women Yael L. Maxwell June 03, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EuroPCR 2022 Registry Data Hint at MACE Benefit With Renal Denervation Michael O'Riordan May 17, 2022